By Tess Stynes
Johnson & Johnson said its first-quarter earnings rose 35%
led by continued sales growth in the health-care company's
pharmaceutical business.
For the year, the company lifted its per-share earnings estimate
by a nickel to $5.80 to $5.90, excluding items, from its previous
range for per-share profit between $5.75 and $5.85.
New Brunswick, N.J.-based J&J, which makes everything from
prescription drugs and medical devices to Band-Aids and Listerine
mouthwash, has been shedding slow-growing products and businesses.
Late last month J&J accepted Carlyle Group LP's offer to
acquire its ortho-clinical diagnostics business for about $4
billion.
The company also has been striving to lower its costs. In
January, J&J outlined plans to cut $1 billion in costs over the
next three years, in part by consolidating some operations and
eliminating jobs.
J&J reported a profit of $4.73 billion, or $1.64 a share, up
from $3.5 billion, or $1.22 a share, a year earlier. Excluding a
tax benefit, acquisition-related expenses and other items, adjusted
earnings rose to $1.54 from $1.44.
Revenue increased 3.5% to $18.12 billion, including a negative
currency impact of 1.8%. Analysts polled by Thomson Reuters
expected per-share profit of $1.47 and revenue of $18 billion.
The company's pharmaceutical business said revenue rose 11% to
$7.5 billion. J&J consumer-products segment posted a sales
decline of 3.2% to $3.6 billion, partly owing to recent
divestitures.
The medical devices segment, which includes the Synthes
business, reported that sales were flat at $7.1 billion.
Write to Tess Stynes at tess.stynes@wsj.com
Access Investor Kit for J&J Snack Foods Corp.
Visit
http://www.companyspotlight.com/partner?cp_code=A591&isin=US4660321096
Access Investor Kit for Johnson & Johnson
Visit
http://www.companyspotlight.com/partner?cp_code=A591&isin=US4781601046
Subscribe to WSJ: http://online.wsj.com?mod=djnwires